ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ANTX AN2 Therapeutics Inc

2.17
0.18 (9.05%)
15 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
AN2 Therapeutics Inc NASDAQ:ANTX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.18 9.05% 2.17 2.03 3.92 2.18 1.959 1.98 123,356 05:00:04

AN2 Therapeutics to Present at Upcoming Investor Conferences

06/11/2023 12:00pm

Business Wire


AN2 Therapeutics (NASDAQ:ANTX)
Historical Stock Chart


From Jun 2023 to Jun 2024

Click Here for more AN2 Therapeutics Charts.

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will participate in two upcoming investor conferences in November.

Stifel 2023 Healthcare Conference

  • Eric Easom, Co-Founder, President and CEO will provide a corporate overview on Wednesday, November 15 at 3:00 p.m. ET.

6th Annual Evercore ISI HealthCONx Conference

  • Eric Easom, Co-Founder, President and CEO will provide a corporate overview on Wednesday, November 29 at 8:45 a.m. ET.

A webcast of the presentations can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our initial candidate is epetraborole, which we are studying as a once-daily, oral treatment with a novel mechanism of action for patients with nontuberculous mycobacteria (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, that leads to irreversible lung damage and can be fatal. For more information, please visit our website at www.an2therapeutics.com.

COMPANY CONTACT: Lucy O. Day Chief Financial Officer l.day@an2therapeutics.com

INVESTOR AND MEDIA CONTACT: Anne Bowdidge ir@an2therapeutics.com

1 Year AN2 Therapeutics Chart

1 Year AN2 Therapeutics Chart

1 Month AN2 Therapeutics Chart

1 Month AN2 Therapeutics Chart